Completed PHASE1 INTERVENTIONAL 2-arm NCT00768469

Study Evaluating Safety And Tolerability, Solid Tumor

A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors

Sponsor: Puma Biotechnology, Inc.

Conditions Advanced Malignant Solid Tumors

Updated 7 times since 2017 Last updated: Apr 24, 2018 Started: Oct 31, 2008 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Malignant Solid Tumors, this trial is completed. The trial is conducted by Puma Biotechnology, Inc. and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Puma Biotechnology, Inc.

Data source: Puma Biotechnology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shizuoka, Japan
• Tokyo, Japan